Drug Trial Radar · NCT07110363
A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer
Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
58
Planned (sponsor's estimate)
Start
Aug 2025
Primary completion
Mar 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Biotroy TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess whether an investigational treatment is safe and tolerable for patients with advanced lung cancer, and to get a preliminary idea of its effectiveness. Participants of all genders, aged between 18 and 75(inclusive), are eligible to join. These patients will receive the investigational drug intravenously every two weeks. If their condition doesn't worsen and they don't experience unbearable side effects, they can continue the treatment for up to two years.
Conditions
- Advanced Malignant Solid Tumor
- Advanced Lung Cancer
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
Interventions
BT02Drug
monoclonal antibody injection with intravenous administration every 2 or 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: through study completion, an average of 2 years
- Dose limited toxicity incidenceTime frame: Through the dose escalation phase , an average of 8 months
- Maximum tolerated dose(MTD)Time frame: Through the dose escalation phase, an average of 8 months
- Recommended Phase II dose (RP2D)Time frame: Through study completion, an average of 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.